Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415].
Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M, Lipton JH, Lee SJ, Szer J, Doocey R, Lewis ID, Huebsch L, Howson-Jan K, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Broady R, Levings M, Fairclough D, Devins G, Szwajcer D, Foley R, Smith C, Panzarella T, Kerr H, Kariminia A, Schultz KR. Couban S, et al. Among authors: lachance s. Biol Blood Marrow Transplant. 2017 Mar;23(3):534. doi: 10.1016/j.bbmt.2016.09.021. Epub 2016 Oct 24. Biol Blood Marrow Transplant. 2017. PMID: 27789277 Free article. No abstract available.
Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: a national review by the Canadian Blood and Marrow Transplant Group.
Kuruvilla J, Pintilie M, Stewart D, Lachance S, Power M, Couture F, Xenocostas A, Voralia M, Couban S, Foley R. Kuruvilla J, et al. Among authors: lachance s. Bone Marrow Transplant. 2010 Jul;45(7):1253-5. doi: 10.1038/bmt.2009.321. Epub 2009 Nov 16. Bone Marrow Transplant. 2010. PMID: 19915625 No abstract available.
Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.
Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M, Lipton JH, Lee SJ, Szer J, Doocey R, Lewis ID, Huebsch L, Howson-Jan K, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Broady R, Levings M, Fairclough D, Devins G, Szwajcer D, Foley R, Smith C, Panzarella T, Kerr H, Kariminia A, Schultz KR. Couban S, et al. Among authors: lachance s. Biol Blood Marrow Transplant. 2016 Aug;22(8):1410-1415. doi: 10.1016/j.bbmt.2016.04.017. Epub 2016 May 3. Biol Blood Marrow Transplant. 2016. PMID: 27154847 Free article. Clinical Trial.
CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results.
Kariminia A, Ivison S, Ng B, Rozmus J, Sung S, Varshney A, Aljurf M, Lachance S, Walker I, Toze C, Lipton J, Lee SJ, Szer J, Doocey R, Lewis I, Smith C, Chaudhri N, Levings MK, Broady R, Devins G, Szwajcer D, Foley R, Mostafavi S, Pavletic S, Wall DA, Couban S, Panzarella T, Schultz KR. Kariminia A, et al. Among authors: lachance s. Haematologica. 2017 Nov;102(11):1936-1946. doi: 10.3324/haematol.2017.170928. Epub 2017 Sep 21. Haematologica. 2017. PMID: 28935847 Free PMC article. Clinical Trial.
Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.
Kim DDH, Popradi G, Lepic K, Paulson K, Allan D, Nampoothiri RV, Lachance S, Deotare U, White J, Elemary M, Jamani K, Fraga C, Lemieux C, Novitzky-Basso I, Law AD, Kumar R, Walker I, Schultz KR; CTTC Chronic GVHD Guideline Working Group. Kim DDH, et al. Among authors: lachance s. Curr Oncol. 2024 Mar 8;31(3):1426-1444. doi: 10.3390/curroncol31030108. Curr Oncol. 2024. PMID: 38534941 Free PMC article.
Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.
Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G, Roy DC, Busque L, Delisle JS, Bambace N, Bernard L, Sabry W, Roy J. Ahmad I, et al. Among authors: lachance s. Bone Marrow Transplant. 2016 Apr;51(4):529-35. doi: 10.1038/bmt.2015.319. Epub 2015 Dec 21. Bone Marrow Transplant. 2016. PMID: 26691426 Clinical Trial.
ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.
Roy DC, Walker I, Maertens J, Lewalle P, Olavarria E, Selleslag D, Lachance S, Buyse M, Wang K, Rovers J, Santi I, Bonig H, Sandler A, Velthuis J, Mielke S. Roy DC, et al. Among authors: lachance s. Leukemia. 2020 Jul;34(7):1907-1923. doi: 10.1038/s41375-020-0733-0. Epub 2020 Feb 11. Leukemia. 2020. PMID: 32047237 Free PMC article. Clinical Trial.
Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective.
Veilleux O, Claveau JS, Alaoui H, Roy J, Ahmad I, Delisle JS, Kiss T, Bambace NM, Bernard L, Cohen S, Sauvageau G, Fleury I, Mollica L, Roy DC, Serroukh Y, Lachance S. Veilleux O, et al. Among authors: lachance s. Transplant Cell Ther. 2022 Mar;28(3):145-151. doi: 10.1016/j.jtct.2021.12.005. Epub 2021 Dec 23. Transplant Cell Ther. 2022. PMID: 34954149 Free article.
111 results